Hydrazine

RTECS #

MU7175000

CAS #

302-01-2
See: NMAM or OSHA Methods

Updated

December 2018

Molecular Weight

32.06

Molecular Formula

H₄N₂

Synonyms

Hydrazine (ACGIH:OSHA)
Hydrazine fume
Hydrazyna (Polish)
Levoxine
Nitrogen hydride
Oxytreat 35
RCRA waste number U133

Skin and Eye Irritation and References

Route/Organism	Dose	Effect	Reference
skin /rabbit	50%/1H		TPKVAL 4,65,1962

Mutation Data and Reference

System Test	Route/Organism/Tissue	Dose	Reference
DNA adduct	/Escherichia coli	10 µmol/L	MUREAV 89,95,1981
DNA Damage	liver/rat	3 mmol/L	MUREAV 113,357,1983
DNA Damage	intraperitoneal/mouse	100 mg/kg	MUREAV 415,1,1998
DNA Damage	oral/mouse	100 mg/kg	MUREAV 415,1,1998
DNA Damage	oral/hamster	15 mg/kg	PAACA3 24,59,1983
DNA Damage	lymphocyte/mammal (species unspecified)	95 pph	BBACAQ 174,591,1969
DNA Damage	lung/rat	0.5 mmol/L/20H	MUREAV 605,94,2006
DNA Damage	lung/human	0.5 mmol/L/20H	MUREAV 605,94,2006
DNA Damage	oral/rat	30 mg/kg	MUREAV 605,94,2006
DNA inhibition	oral/rat	60 mg/kg	CRNGDP 4,953,1983
DNA inhibition	oral/mouse	200 mg/kg	MUREAV 46,305,1977
DNA inhibition	HeLa cell/human	50 µmol/L	CNREA8 44,59,1984
morphological transform	liver/human	80 µg/L	BJCAAI 37,873,1978
morphological transform	other cell types/human	35 mg/L	ITCSAF 17,719,1981
morphological transform	kidney/hamster	80 µg/L	BJCAAI 37,873,1978
mutation in mammalian somatic cells	lymphocyte/mouse	1 mmol/L	MUREAV 89,321,1981
mutation in microorganisms	/Saccharomyes cerevisiae	200 mmol/L (-enzymatic activation step)	MUREAV 93,339,1982
mutation in microorganisms	/Haemophilus influenzae	2 mmol/L (-enzymatic activation step)	MUREAV 30,9,1975
mutation in microorganisms	/Other microorganisms	70 µg/L (-enzymatic activation step)	MUREAV 173,233,1986
mutation in microorganisms	/Salmonella typhimurium	120 µg/plate (-enzymatic activation step)	BIZNAT 97,137,1978
mutation in microorganisms	/Escherichia coli	4300 µmol/L (+enzymatic activation step)	TOLED5 31,131,1986
other mutation test systems	/Escherichia coli	80 pmol/tube	MUREAV 147,79,1985
other mutation test systems	/Bacillus subtilis	10 mmol/L	MUREAV 5,343,1968
sex chromosome loss and nondisjunction	oral/Drosophila melanogaster	10 mmol/L	MUREAV 16,363,1972
Unscheduled DNA Synthesis	oral/rat	60 mg/kg	CRNGDP 4,953,1983
Unscheduled DNA Synthesis	lung/rat	250 µg/L	NTIS** AD-A075-605
Unscheduled DNA Synthesis	ovary/hamster	250 µg/L	NTIS** AD-A075-605
Unscheduled DNA Synthesis	lung/hamster	250 µg/L	NTIS** AD-A075-605

Reproductive Effects Data and References

Route/Organism	Dose	Effect	Reference
inhalation/rat	4 mg/m³/2H (7-20D pregnant)	Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants)	GISAAA 39(10),23,1974
inhalation/rat	1 mg/m³/24H (1-11D pregnant)	Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) Reproductive: Effects on embryo or fetus: Fetal death	GISAAA 39(10),23,1974
inhalation/hamster	1 ppm/6H (1Y male)	Reproductive: Paternal effects: Testes, epididymis, sperm duct	FAATDF 5,1050,1985
inhalation/rat	1 mg/m³ (1-22D pregnant)	Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus)	VCVN5* -,20,1989
intraperitoneal/mouse	48 mg/kg (6-9D pregnant)	Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) Reproductive: Specific developmental abnormalities: Musculoskeletal system	NTIS** AD-A084-023
intraperitoneal/mouse	80 mg/kg (6-9D pregnant)	Reproductive: Specific developmental abnormalities: Central nervous system Reproductive: Specific developmental abnormalities: Urogenital system	NTIS** AD-A084-023
intraperitoneal/rat	100 mg/kg (6-15D pregnant)	Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants)	APTOD9 19,A21,1980
intraperitoneal/rat	50 mg/kg (6-15D pregnant)	Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus)	APTOD9 19,A21,1980
intraperitoneal/rat	30 mg/kg (7-9D pregnant)	Reproductive: Specific developmental abnormalities: Central nervous system Reproductive: Specific developmental abnormalities: Musculoskeletal system Reproductive: Specific developmental abnormalities: Urogenital system	NTIS** AD-A119-706
intraperitoneal/rat	30 mg/kg (7-9D pregnant)	Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants) Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus)	NTIS** AD-A119-706
skin/rat	50 mg/kg (9D pregnant)	Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants)	NTIS** AD-A119-706
subcutaneous/rat	80 mg/kg (11-20D pregnant)	Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) Reproductive: Effects on embryo or fetus: Fetal death Reproductive: Effects on newborn: Viability index (e.g., # alive at day 4 per # born alive)	AEHLAU 21,615,1970

Tumorigenic Data and References

Route/Organism	Dose	Effect	Reference
inhalation/hamster	lowest published toxic concentration: 1 ppm/6H/1Y- intermittent	Tumorigenic: Equivocal tumorigenic agent by RTECS criteria Gastrointestinal: Colon tumors	FAATDF 5,1050,1985
inhalation/hamster	toxic concentration: 5 ppm/6H/1Y- intermittent	Tumorigenic: Equivocal tumorigenic agent by RTECS criteria Olfaction: Tumors	PAACA3 21,74,1980
inhalation/mouse	lowest published toxic concentration: 1 ppm/6H/1Y- intermittent	Tumorigenic: Equivocal tumorigenic agent by RTECS criteria Olfaction: Tumors	PAACA3 21,74,1980
inhalation/rat	lowest published toxic concentration: 5 ppm/6H/1Y- intermittent	Tumorigenic: Carcinogenic by RTECS criteria Endocrine: Thyroid tumors	FAATDF 5,1050,1985
inhalation/rat	toxic concentration: 5 ppm/6H/1Y- intermittent	Tumorigenic: Equivocal tumorigenic agent by RTECS criteria Olfaction: Tumors	PAACA3 21,74,1980
inhalation/rat	toxic concentration: 1 ppm/6H/1Y- intermittent	Tumorigenic: Equivocal tumorigenic agent by RTECS criteria Olfaction: Tumors	PAACA3 21,74,1980
intraperitoneal/mouse	lowest published toxic dose: 400 mg/kg/5W- intermittent	Tumorigenic: Carcinogenic by RTECS criteria Blood: Tumors Blood: Leukemia	UICMAI 7,180,1967
oral/mouse	lowest published toxic dose: 1951 mg/kg/2Y- continuous	Tumorigenic: Neoplastic by RTECS criteria Lung, Thorax, or Respiration: Tumors Blood: Lymphoma including Hodgkin's disease	IJCNAW 9,109,1972
oral/rat	lowest published toxic dose: 900 mg/kg/2Y- continuous	Tumorigenic: Neoplastic by RTECS criteria Liver: Tumors	EXPADD 33,133,1988

Acute Toxicity Data and References

Route/Organism	Dose	Effect	Reference
inhalation/mouse	lethal concentration (50 percent kill): 252 ppm/4H	Eye: Other eye effects Behavioral: Convulsions or effect on seizure threshold Lung, Thorax, or Respiration: Dyspnea	AMIHAB 12,609,1955
inhalation/mouse	lethal concentration (50 percent kill): 1000 mg/m³/2H		VCVN5* -,20,1993
inhalation/mouse	lethal concentration (50 percent kill): 320 mg/m³/4H		VCVN5* -,20,1993
inhalation/mouse	lethal concentration (50 percent kill): 330 gm/m³	Lung, Thorax, or Respiration: Acute pulmonary edema Liver: Fatty liver degeneration Liver: Other changes	TPKVAL 4,65,1962
inhalation/mouse	Lowest published lethal concentration: 1.5 gm/m³/2H	Kidney, Ureter, and Bladder: Changes in tubules (including acute renal failure, acute tubular necrosis) Blood: Hemorrhage Blood: Changes in spleen	TPKVAL 4,65,1962
inhalation/mouse	lowest published toxic concentration: 0.65 gm/m³/2H	Brain and Coverings: Other degenerative changes Lung, Thorax, or Respiration: Changes in pulmonary vascular resistance Liver: Fatty liver degeneration	TPKVAL 4,65,1962
inhalation/mouse	lowest published toxic concentration: 0.02 gm/m³		TPKVAL 4,65,1962
inhalation/rat	lethal concentration (50 percent kill): 750 gm/m³/4H	Brain and Coverings: Increased intracranial pressure Cardiac: Other changes Lung, Thorax, or Respiration: Changes in pulmonary vascular resistance	TPKVAL 4,65,1962
inhalation/rat	Lowest published lethal concentration: 0.02 gm/m³	Kidney, Ureter, and Bladder: Other changes Blood: Hemorrhage	TPKVAL 4,65,1962
inhalation/rat	Lowest published lethal concentration: 1.5 gm/m³/2H	Behavioral: Somnolence (general depressed activity) Lung, Thorax, or Respiration: Structural or functional change in trachea or bronchi Nutritional and Gross Metabolic: Weight loss or decreased weight gain	TPKVAL 4,65,1962
inhalation/rat	lowest published toxic concentration: 0.65 gm/m³/2H	Behavioral: Alteration of classical conditioning	TPKVAL 4,65,1962
inhalation/rat	lowest published toxic concentration: 20000 mg/m³/4H	Lung, Thorax, or Respiration: Structural or functional change in trachea or bronchi Behavioral: Excitement Behavioral: Tetany	VCVN5* -,20,1993
inhalation/rat	lethal concentration (50 percent kill): 130 mg/m³/2H		VCVN5* -,20,1993
inhalation/rat	lowest published toxic concentration: 23 ppm/10M	Olfaction: Deviated nasal septum	TOXID9 44,303,2005
inhalation/rat	lowest published toxic concentration: 16 ppm/30M	Olfaction: Deviated nasal septum	TOXID9 44,303,2005
inhalation/rat	lowest published toxic concentration: 13 ppm/1H	Olfaction: Deviated nasal septum	TOXID9 44,303,2005
inhalation/rat	lowest published toxic concentration: 3.1 ppm/4H	Olfaction: Deviated nasal septum	TOXID9 44,303,2005
inhalation/rat	lowest published toxic concentration: 1.6 ppm/8H	Olfaction: Deviated nasal septum	TOXID9 44,303,2005
inhalation/rat	Lowest published lethal concentration: 64 ppm/10M		TOXID9 44,303,2005
inhalation/rat	Lowest published lethal concentration: 45 ppm/30M		TOXID9 44,303,2005
inhalation/rat	Lowest published lethal concentration: 35 ppm/1H		TOXID9 44,303,2005
inhalation/rat	Lowest published lethal concentration: 8.9 ppm/4H		TOXID9 44,303,2005
inhalation/rat	Lowest published lethal concentration: 4.4 ppm/8H		TOXID9 44,303,2005
inhalation/rat	lethal concentration (50 percent kill): 570 ppm/4H	Eye: Other eye effects Behavioral: Convulsions or effect on seizure threshold Lung, Thorax, or Respiration: Dyspnea	AMIHAB 12,609,1955
intramuscular/Dog	lethal dose (50 percent kill): 16500 µg/kg		GISAAA 16(6),53,1972
intramuscular/rabbit	lethal dose (50 percent kill): 38500 µg/kg		GISAAA 16(6),53,1972
intramuscular/rat	lethal dose (50 percent kill): 53500 µg/kg		GISAAA 16(6),53,1972
intraperitoneal/cat	lowest published toxic dose: 20 mg/kg	Behavioral: Tetany	VCVN5* -,20,1993
intraperitoneal/mouse	lethal dose (50 percent kill): 62 mg/kg		MEPAAX 24,71,1973
intraperitoneal/mouse	lowest published toxic dose: 100 mg/kg	Liver: Other changes Blood: Other changes Biochemical: Metabolism (intermediary): Lipids including transport	TOXID9 72,94,2003
intraperitoneal/rat	lethal dose (50 percent kill): 59 mg/kg		MEPAAX 24,71,1973
intraperitoneal/rat	lowest published toxic dose: 20 mg/kg	Behavioral: Alteration of classical conditioning	VCVN5* -,20,1993
intravenous/Dog	lethal dose (50 percent kill): 25 mg/kg		MEPAAX 24,71,1973
intravenous/Dog	lowest published lethal dose: 25 mg/kg	Liver: Other changes Kidney, Ureter, and Bladder: Other changes Blood: Hemorrhage	TPKVAL 4,65,1962
intravenous/mouse	lowest published lethal dose: 55 mg/kg	Brain and Coverings: Other degenerative changes Behavioral: Somnolence (general depressed activity) Behavioral: Convulsions or effect on seizure threshold	TPKVAL 4,65,1962
intravenous/mouse	lethal dose (50 percent kill): 57 mg/kg		MEPAAX 24,71,1973
intravenous/rabbit	lethal dose (50 percent kill): 20 mg/kg		AMIHBC 9,199,1954
intravenous/rat	lethal dose (50 percent kill): 55 mg/kg		MEPAAX 24,71,1973
intravenous/rat	lowest published lethal dose: 55 mg/kg	Behavioral: Excitement Lung, Thorax, or Respiration: Acute pulmonary edema Lung, Thorax, or Respiration: Dyspnea	TPKVAL 4,65,1962
oral/mouse	lowest published toxic dose: 250 mg/kg	Liver: Fatty liver degeneration Nutritional and Gross Metabolic: Weight loss or decreased weight gain	TXAPA9 204,135,2005
oral/mouse	lowest published toxic dose: 100 mg/kg	Liver: Other changes Biochemical: Metabolism (intermediary): Lipids including transport Biochemical: Metabolism (intermediary): Other proteins	TOXID9 78,353,2004
oral/mouse	lowest published toxic dose: 300 mg/kg	Liver: Multiple effects Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Multiple enzyme effects Biochemical: Metabolism (intermediary): Lipids including transport	TOXID9 78,353,2004
oral/mouse	lowest published toxic dose: 100 mg/kg	Liver: Other changes Blood: Other changes Biochemical: Metabolism (intermediary): Lipids including transport	TOXID9 72,94,2003
oral/mouse	lethal dose (50 percent kill): 80 mg/kg	Liver: Fatty liver degeneration Kidney, Ureter, and Bladder: Changes in tubules (including acute renal failure, acute tubular necrosis) Blood: Changes in spleen	TPKVAL 4,65,1962
oral/mouse	lethal dose (50 percent kill): 59 mg/kg		MEPAAX 24,71,1973
oral/mouse	lethal dose (50 percent kill): 59 mg/kg	Lung, Thorax, or Respiration: Acute pulmonary edema Kidney, Ureter, and Bladder: Changes in kidney weight	VCVN5* -,20,1993
oral/rat	lethal dose (50 percent kill): 60 mg/kg	Lung, Thorax, or Respiration: Acute pulmonary edema Kidney, Ureter, and Bladder: Changes in kidney weight	VCVN5* -,20,1993
oral/rat	lowest published toxic dose: 90 mg/kg	Liver: Hepatitis (hepatocellular necrosis), diffuse Liver: Fatty liver degeneration Nutritional and Gross Metabolic: Weight loss or decreased weight gain	TXAPA9 204,135,2005
oral/rat	lethal dose (50 percent kill): 60 mg/kg		MEPAAX 24,71,1973
oral/rat	lowest published toxic dose: 75 mg/kg	Nutritional and Gross Metabolic: Weight loss or decreased weight gain	CRTOEC 14,975,2001
oral/rat	lowest published toxic dose: 90 mg/kg	Kidney, Ureter, and Bladder: Other changes in urine composition Blood: Changes in leukocyte (WBC) count Blood: Changes in other cell count (unspecified)	CRTOEC 14,975,2001
oral/rat	lowest published toxic dose: 120 mg/kg	Liver: Hepatitis (hepatocellular necrosis), zonal Liver: Fatty liver degeneration Liver: Other changes	CRTOEC 14,975,2001
skin/Dog	lowest published lethal dose: 96 mg/kg		TXAPA9 21,186,1972
skin/Dog	lowest published toxic dose: 3 mg/kg	Behavioral: Tetany Behavioral: Alteration of classical conditioning	VCVN5* -,20,1993
skin/guinea pig	lethal dose (50 percent kill): 190 mg/kg	Behavioral: Convulsions or effect on seizure threshold	XAWPA2 CWL 2-10,1958
skin/rabbit	lethal dose (50 percent kill): 91 mg/kg		AMIHBC 9,199,1954
subcutaneous/mouse	lowest published toxic dose: 30 mg/kg	Blood: Changes in leukocyte (WBC) count Immunological Including Allergic: Increase in cellular immune response	TXCYAC 172,35,2002
unreported route/mouse	lethal dose (50 percent kill): 200 mg/kg		BJCAAI 6,160,1952

Other Multiple Dose Data and References

Route/Organism	Dose	Effect	Reference
inhalation/Dog	lowest published toxic concentration: 14 ppm/6H/26W- intermittent	Behavioral: Food intake (animal) Behavioral: Muscle weakness Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field	AMIHBC 10,476,1954
inhalation/guinea pig	lowest published toxic concentration: 14 ppm/6H/14W- intermittent	Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field	AMIHBC 10,476,1954
inhalation/guinea pig	lowest published toxic concentration: 5 mg/m³/24H/59D- continuous	Lung, Thorax, or Respiration: Other changes	VCVN5* -,20,1989
inhalation/hamster	lowest published toxic concentration: 1 ppm/6H/1Y- intermittent	Liver: Other changes Kidney, Ureter, and Bladder: Other changes Endocrine: Other changes	NTIS** AD-A086-341
inhalation/monkey	lowest published toxic concentration: 1 ppm/24H/90D- continuous	Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field	NTIS** AD-A086-341
inhalation/mouse	lowest published toxic concentration: 130 mg/m³/1H/17W- intermittent	Blood: Normocytic anemia Blood: Changes in leukocyte (WBC) count	VCVN5* -,20,1989
inhalation/mouse	lowest published toxic concentration: 1 ppm/24H/90D- continuous	Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field	NTIS** AD-A086-341
inhalation/mouse	lowest published toxic concentration: 14 ppm/6H/5W- intermittent	Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field	AMIHBC 10,476,1954
inhalation/mouse	lowest published toxic concentration: 0.003 gm/m³/30D- intermittent	Lung, Thorax, or Respiration: Changes in pulmonary vascular resistance Blood: Changes in spleen Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field	TPKVAL 4,65,1962
inhalation/rat	lowest published toxic concentration: 0.003 gm/m³/91D- intermittent	Lung, Thorax, or Respiration: Changes in pulmonary vascular resistance Blood: Changes in spleen Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field	TPKVAL 4,65,1962
inhalation/rat	lowest published toxic concentration: 0.0005 gm/m³/30D- intermittent	Peripheral Nerve and Sensation: Recording from peripheral motor nerve	TPKVAL 4,65,1962
inhalation/rat	lowest published toxic concentration: 0.0005 gm/m³/213D- intermittent	Behavioral: Alteration of classical conditioning Kidney, Ureter, and Bladder: Changes in tubules (including acute renal failure, acute tubular necrosis) Blood: Hemorrhage	TPKVAL 4,65,1962
inhalation/rat	lowest published toxic concentration: 1 ppm/24H/90D- continuous	Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field	NTIS** AD-A086-341
inhalation/rat	lowest published toxic concentration: 5 ppm/6H/26W- intermittent	Behavioral: Muscle weakness Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field	AMIHBC 10,476,1954
inhalation/rat	lowest published toxic concentration: 10 mg/m³/4H/30D- intermittent	Liver: Liver function tests impaired Kidney, Ureter, and Bladder: Other changes in urine composition Blood: Changes in bone marrow not included in above	GISAAA 40(3),29,1975

Reviews

Organization	Standard	Reference
American Conference of Governmental Industrial Hygienists (ACGIH)	Threshold Limit Value-time-weighted average 0.01 ppm (skin)	DTLVS* TLV/BEI,2013
American Conference of Governmental Industrial Hygienists (ACGIH)	Threshold Limit Value-Confirmed animal carcinogen	DTLVS* TLV/BEI,2013
International Agency for Research on Cancer (IARC)	Cancer Review:Animal Sufficient Evidence	IMEMDT 4,127,1974
International Agency for Research on Cancer (IARC)	Cancer Review:Animal Sufficient Evidence	IMEMDT 71,991,1999
International Agency for Research on Cancer (IARC)	Cancer Review:Human Inadequate Evidence	IMSUDL 7,223,1987
International Agency for Research on Cancer (IARC)	Cancer Review:Human Inadequate Evidence	IMEMDT 71,991,1999
International Agency for Research on Cancer (IARC)	Cancer Review:Group 2B	IMEMDT 71,991,1999
TOXICOLOGY REVIEW		AMIHBC 9,199,1954
TOXICOLOGY REVIEW		ATXKA8 28,135,1971
TOXICOLOGY REVIEW		MUREAV 627,10,2007
TOXICOLOGY REVIEW		ENTOX* -,536,2005
TOXICOLOGY REVIEW		MUREAV 584,1,2005
TOXICOLOGY REVIEW		HUTOX* -,719,1996
TOXICOLOGY REVIEW		ISMEA* 10,302,2008
TOXICOLOGY REVIEW		MUTAEX 25,335,2010
TOXICOLOGY REVIEW		MUREAV 762,76,2014
TOXICOLOGY REVIEW		MUREAV 743,10,2012
TOXICOLOGY REVIEW		FCTOD7 55,596,2013
TOXICOLOGY REVIEW		MUREAV 771,85,2017
TOXICOLOGY REVIEW		FCTOD7 107,502,2017
TOXICOLOGY REVIEW		RTOPDW 54,247,2009
TOXICOLOGY REVIEW		RTOPDW 55,43,2009

Standards and Regulations

Organization	Standard	Reference
Mine Safety and Health Administration (MSHA) STANDARD-air	time-weighted average 1 ppm (1.3 mg/m³) (skin)	DTLVS* 3,127,1971
Occupational Exposure Limit IN ARGENTINA, BULGARIA, COLOMBIA, JORDAN check ACGIH TLV;
Occupational Exposure Limit IN SINGAPORE, VIETNAM check ACGIH TLV
Occupational Exposure Limit-AUSTRALIA	time-weighted average 0.01 ppm (0.013 mg/m³), Carcinogen, JUL2008
Occupational Exposure Limit-AUSTRIA	TRK-TMW 0.1 ppm (0.13 mg/m³);KZW 0.4 ppm (0.52 mg/m³), skin, sen, 2007
Occupational Exposure Limit-BELGIUM	time-weighted average 0.01 ppm (0.013 mg/m³), Skin, Carcinogen, MAR2002
Occupational Exposure Limit-DENMARK	time-weighted average 0.01 ppm (0.013 mg/m³), skin, carc, MAY2011
Occupational Exposure Limit-FINLAND	time-weighted average 0.1 ppm (0.13 mg/m³), short term exposure limit 0.3 ppm (0.4 mg/m³), skin, NOV2011
Occupational Exposure Limit-FRANCE	VME 0.1 ppm (0.1 mg/m³), FEB2006
Occupational Exposure Limit-HUNGARY	ceiling concentration 0.13 mg/m³, Carcinogen, SEP2000
Occupational Exposure Limit-ICELAND	time-weighted average 0.1 ppm (0.13 mg/m³), carc, skin, sen, NOV2011
Occupational Exposure Limit-JAPAN	Occupational Exposure Limit 0.1 ppm (0.13 mg/m³), skin, 2B carc, s1 sen, MAY2012
Occupational Exposure Limit-KOREA	time-weighted average 0.1 ppm (0.13 mg/m³), skin, 2006
Occupational Exposure Limit-MEXICO	time-weighted average 0.1 ppm (0.1 mg/m³), 2004
Occupational Exposure Limit-NEW ZEALAND	time-weighted average 0.01 ppm (0.013 mg/m³), skin, JAN2002
Occupational Exposure Limit-NORWAY	time-weighted average 0.1 ppm (0.13 mg/m³), JAN1999
Occupational Exposure Limit-PERU	time-weighted average 0.01 ppm (0.013 mg/m³), JUL2005
Occupational Exposure Limit-POLAND	MAC(time-weighted average) 0.05 mg/m³, MAC(short term exposure limit) 0.1 mg/m³, JAN1999
Occupational Exposure Limit-RUSSIA	short term exposure limit 0.1 mg/m³, Skin, JUN2003
Occupational Exposure Limit-SWEDEN	Group B Carcinogen, JUN2005
Occupational Exposure Limit-SWITZERLAND	MAK-week 0.1 ppm (0.13 mg/m³), carc 2, skin, sen, JAN2011
Occupational Exposure Limit-THE PHILIPPINES	time-weighted average 1 ppm (1.3 mg/m³), Skin, JAN1993
Occupational Exposure Limit-TURKEY	time-weighted average 1 ppm (1.3 mg/m³), Skin, JAN1993
Occupational Exposure Limit-UNITED KINGDOM	time-weighted average 0.02 ppm (0.03 mg/m³);short term exposure limit 0.1 ppm (0.13 mg/m³), carc, skin, OCT2007
Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Construction)	8H time-weighted average 1 ppm (1.3 mg/m³) (skin)	CFRGBR 29,1926.55,1994
Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Federal Contractors)	8H time-weighted average 1 ppm (1.3 mg/m³) (skin)	CFRGBR 41,50-204.50,1994
Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (General Industry)	8H time-weighted average 1 ppm (1.3 mg/m³) (skin)	CFRGBR 29,1910.1000,1994
Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Shipyards)	8H time-weighted average 1 ppm (1.3 mg/m³) (skin)	CFRGBR 29,1915.1000,1993

NIOSH Documentation and Surveillance

Organization	Standard	Reference
National Institute for Occupational Safety and Health (NIOSH) Recommended Exposure Level TO HYDRAZINES-air	Carcinogen ceiling concentration 0.03 ppm/120M	NIOSH* DHHS #92-100,1992
National Occupational Exposure Survey 1983	Hazard Code 38110; Number of Industries 44; Total Number of Facilities 2515; Number of Occupations 46; Total Number of Employees Exposed 60490; Total Number of Female Employees Exposed 2841
National Occupational Hazard Survey 1974	Hazard Code 38110; Number of Industries 37; Total Number of Facilities 2134; Number of Occupations 27; Total Number of Employees Exposed 11185

Status in Federal Agencies

Organization	Reference
ATSDR TOXICOLOGY PROFILE (NTIS** PB/98/101025/AS)
EPA GENETOX PROGRAM 1988, Inconclusive: D melanogaster Sex-linked lethal
EPA GENETOX PROGRAM 1988, Positive: Carcinogenicity-mouse/rat
EPA TSCA Section 8(b) CHEMICAL INVENTORY
EPA TSCA Section 8(d) unpublished health/safety studies
EPA TSCA Section 8(e) Risk Notification, 8EHQ-1292-8619;8EHQ-0593-9056
EPA TSCA TEST SUBMISSION (TSCATS) DATA BASE, JANUARY 2001
NIOSH Analytical Method, 1994: Hydrazine, 3503
NTP 14th Report on Carcinogens,2016:Reasonably anticipated to be human carcinogen
On EPA IRIS database
OSHA ANALYTICAL METHOD #108
OSHA ANALYTICAL METHOD #20

Page last reviewed: November 16, 2018

Content source: National Institute for Occupational Safety and Health